COIMBRA, Portugal, June 26, 2017 /PRNewswire/ -- At the
16th International Photodynamic Association (IPA) World
Congress in Coimbra, Dr. Nicolas
Loebel was the recipient of the 2017 CLINICAL PDT RESEARCH
EXCELLENCE AWARD.
Dr. Loebel is the President and Chief Technology Officer of
Ondine Biomedical Inc., a Canadian company developing and
commercializing antimicrobial photodynamic therapies to treat and
prevent multidrug resistant infections. Over the past 15 years, Dr.
Loebel and his team at Ondine Research Laboratories have developed
5 antimicrobial photodynamic products, including Periowave™ (oral
infections), Sinuwave™ (sinus infections), MRSAid™ (nasal
decolonization), Steriwave™ (skin infections) and Exelume™ (VAP
reduction). More than 300,000 patients have been treated with
these technologies in Canada and
elsewhere, demonstrating excellent clinical outcomes and safety
profiles.
The Coimbra World Congress was the 16th conference
held by the International Photodynamic Association, marking 32
years of this global meeting. The IPA World Congresses, held every
two years, are the leading PDT meetings bringing together members
of the global photodynamic community in order to advance scientific
and clinical research relating to photodiagnosis and photodynamic
therapies. The next IPA World Congress is to be hosted in
Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the
Wellman Center for Photomedicine, Harvard
Medical School (HMS) and a Professor of Health Sciences and
Technology (Harvard-MIT).
About Photodynamic Therapy
Photodynamic Therapy (PDT), a technology developed in the
1980's, is a combination therapy involving light activated
photosensitizers to diagnose and treat various types of cancers and
pre-cancers, macular degeneration and multidrug resistant biofilm
infections involving bacteria, viruses and fungi.
For further information:
ipasecretary@internationalphotodynamic.com
Photo -
http://mma.prnewswire.com/media/527933/NLoebel_Picture.jpg